Stephen Schuster, MD, Gives Advice for Treating Aggressive Lymphomas During COVID-19 Pandemic

Article

Stephen Schuster, MD, talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.

Stephen Schuster, MD, of Penn Medicine talked about the benefits of conducting routine visits remotely during the COVID-19 pandemic, allowing doctors to see and treat more patients safely and efficiently.

Transcription:

As I said, some of our visits that are very routine can be done remotely. That actually saves time, number 1, and it also reduces traffic to the cancer center and through the waiting room and into the exam room. I think if we can continue to maintain that, we’ll have greater capacity to see patients that need to be seen. People that are being evaluated up front with either a new diagnosis or for evaluation for CAR T, we’ll be able to bring more patients in because our schedule won’t be quite as cluttered with routine follows up, which we can still do, but we can do more efficiently and remotely. We’ll have more space in clinic, more space in our schedules, and probably be able to handle a greater volume of patients.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Related Content